In summary, the stable binding of Resmetirom with ERN1 and SLC11A1 suggests its potential to mitigate NAFLD progression by modulating IM-FT target protein expression. This evidence concerns the gene ERN1 and metabolic dysfunction-associated steatotic liver disease.